A Phase II Study of Bortezomib in Combination With Dexamethasone in Patients With Relapsed Hodgkin's Lymphoma

University of Cologne1 site in 1 country37 target enrollmentMarch 2005

ConditionsHodgkin Disease

DrugsBortezomib Dexamethasone

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Hodgkin Disease
Sponsor: University of Cologne
Enrollment: 37
Locations: 1
Primary Endpoint: Overall response rate (complete and partial responses)
Status: Terminated
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.

Detailed Description

The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.

Registry

clinicaltrials.gov

Start Date

March 2005

End Date

TBD

Last Updated

17 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

University of Cologne

Eligibility Criteria

Inclusion Criteria

•Hodgkin's lymphoma
•Second or higher relapse (first relapse if high-dose chemotherapy not possible)
•Age \>/= 18 years
•No major organ dysfunction or intercurrent disorder
•Written informed consent